Cargando…

Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence

Acamprosate (calcium acetylhomotaurine) is an amino acid modulator that has displayed efficacy in some clinical trials in reducing craving and promoting abstinence in alcohol dependent patients following detoxification. While acamprosate is safe and generally well-tolerated, not all studies have dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yahn, Stephanie L., Watterson, Lucas R., Olive, M. Foster
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565569/ https://www.ncbi.nlm.nih.gov/pubmed/23399877 http://dx.doi.org/10.4137/SART.S9345

Ejemplares similares

Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
por: Witkiewitz, Katie, et al.
Publicado: (2012)

Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
por: Hinton, David J., et al.
Publicado: (2017)

A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence
por: Kumar, Arun, et al.
Publicado: (2020)

Acamprosate: a new tool in the battle against alcohol dependence
por: Wright, Tara M, et al.
Publicado: (2006)

Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence
por: Woo, Jungmin, et al.
Publicado: (2014)

Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate
por: Karpyak, V M, et al.
Publicado: (2014)

Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
por: Nam, H W, et al.
Publicado: (2015)

Rare Anaphylactic Reaction to Acamprosate in a Young Alcoholic
por: Patnaik, Asha, et al.
Publicado: (2019)

Tinnitus treatment with acamprosate: double-blind study
por: Azevedo, Andréia A., et al.
Publicado: (2015)

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2012)

Role of acamprosate in sensorineural tinnitus
por: Sharma, Dinesh Kumar, et al.
Publicado: (2012)

Unusual side effects with acamprosate
por: Sidana, Ajeet Kumar, et al.
Publicado: (2007)

PM321. DNA Methylation Signature Associated with Abstinence in Alcoholics Treated with Acamprosate
por: Hlady, R., et al.
Publicado: (2016)

Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
por: Ho, Ming-Fen, et al.
Publicado: (2022)

Calcium acamprosate: a triclinic polymorph
por: Maccaroni, Elisabetta, et al.
Publicado: (2011)

Adherence to Prescribed Acamprosate in Alcohol Dependence and 1-Year Morbidities and Mortality: Utilizing a Data Linkage Methodology
por: Tolomeo, Serenella, et al.
Publicado: (2021)

Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
por: Watterson, Lucas R., et al.
Publicado: (2013)

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
por: Ho, Ming‐Fen, et al.
Publicado: (2022)

TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)

Deterrent Action of Acamprosate: A Case Report
por: Spoorthy, Mamidipalli Sai, et al.
Publicado: (2019)

Six-Month Outcome in Bipolar Spectrum Alcoholics Treated with Acamprosate after Detoxification: A Retrospective Study
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2014)

Acamprosate-induced myoclonic jerks: A rare side effect
por: Soni, Puneet Kumar, et al.
Publicado: (2021)

Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug–Drug Interactions
por: Antonescu, Irina E., et al.
Publicado: (2020)

PM307. Untargeted Global Metabolomics Reveals Metabolites Associated with Acamprosate Treatment Outcome
por: Ho, Ada, et al.
Publicado: (2016)

Early central Glutamate and GABA changes with Baclofen and Acamprosate among patients with alcohol dependence syndrome: A magnetic resonance spectroscopy based prospective study
por: Khanra, Sourav, et al.
Publicado: (2022)

Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease
por: Hajj, Rodolphe, et al.
Publicado: (2015)

Acamprosate and Baclofen were Not Effective in the Treatment of Pathological Gambling: Preliminary Blind Rater Comparison Study
por: Dannon, Pinhas N., et al.
Publicado: (2011)

Sodium acamprosate and calcium exert additive effects on nucleus accumbens dopamine in the rat
por: Ademar, Karin, et al.
Publicado: (2022)

Hypersalivation and coarse tremors as uncommon side effects of acamprosate: A case report
por: Bhandutia, D., et al.
Publicado: (2021)

The rates and measurement of adherence to acamprosate in randomised controlled clinical trials: A systematic review
por: Donoghue, Kim, et al.
Publicado: (2022)

Acamprosate reduces ethanol intake in the rat by a combined action of different drug components
por: Ademar, Karin, et al.
Publicado: (2023)

Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis
por: Boussicault, Lydie, et al.
Publicado: (2020)

Differential Modulation of Thresholds for Intracranial Self-Stimulation by mGlu5 Positive and Negative Allosteric Modulators: Implications for Effects on Drug Self-Administration
por: Cleva, Richard M., et al.
Publicado: (2012)

Positive or negative allosteric modulation of metabotropic glutamate receptor 5 (mGluR5) does not alter expression of behavioral sensitization to methamphetamine
por: Kufahl, Peter R, et al.
Publicado: (2013)

Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France
por: Chaignot, Christophe, et al.
Publicado: (2018)

Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety
por: Schaefer, Tori L., et al.
Publicado: (2017)

Long‐term safety and efficacy of nalmefene in Japanese patients with alcohol dependence
por: Higuchi, Susumu, et al.
Publicado: (2020)

Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression
por: Phimarn, Wiraphol, et al.
Publicado: (2023)

Role of vitamin B12 deficiency in ischemic stroke risk and outcome
por: Yahn, Gyllian B., et al.
Publicado: (2020)

Effects of α‐Pyrrolidinopentiophenone and 4-Methyl-N-Ethylcathinone, Two Synthetic Cathinones Commonly Found in Second-Generation “Bath Salts,” on Intracranial Self-Stimulation Thresholds in Rats
por: Watterson, Lucas R., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mkmqhspqupupnjc74dgk1sijjc